Viridian Therapeutics Stock Falls 31% Despite Reporting Positive Topline Data From Elegrobart Study

Shares of Viridian Therapeutics fell about 31% on Monday despite the company announcing positive topline results from the elegrobart REVEAL-1 Phase 3 trial in active thyroid eye disease. The sharp selloff suggests investor skepticism or other adverse catalysts outweighing the positive readout; further detail from full data, regulatory commentary, or analyst reactions is likely to drive near-term price action.

Analysis

Shares of Viridian Therapeutics fell about 31% on Monday despite the company announcing positive topline results from the elegrobart REVEAL-1 Phase 3 trial in active thyroid eye disease. The sharp selloff suggests investor skepticism or other adverse catalysts outweighing the positive readout; further detail from full data, regulatory commentary, or analyst reactions is likely to drive near-term price action.